Welcome to our dedicated page for Arch Biopartners news (Ticker: ACHFF), a resource for investors and traders seeking the latest updates and insights on Arch Biopartners stock.
Arch Biopartners Inc. develops therapeutics for acute kidney injury and chronic kidney disease. Company news centers on LSALT peptide for cardiac surgery-associated acute kidney injury, cilastatin for drug-toxin-related acute kidney injury, and a chronic kidney disease platform tied to interleukin-32.
Recurring updates include clinical trial agreements, ethics and operational approvals, hospital site activity, patient recruitment and dosing milestones, drug-product manufacturing for cilastatin, patent filings connected with the CKD platform, and board governance changes. The company’s disclosures also describe acute kidney injury mechanisms such as ischemia-reperfusion injury, nephrotoxic pharmaceuticals, and inflammation-related kidney damage.
Summary not available.
Summary not available.
Arch Biopartners Inc. (OTCQB: ACHFF) announced a successful increase in the maximum daily dose of its lead drug candidate, LSALT peptide, to 20 mg in a human trial in Australia. This trial confirmed the safety and tolerability of the new dosage, paving the way for a Phase II trial aimed at treating cardiac surgery-associated acute kidney injury (CS-AKI). Previously, LSALT peptide was administered at a maximum of 5 mg during a Phase II trial for COVID-19 patients. Arch is also advancing the production of 10,000 vials of LSALT peptide for future non-COVID trials, expected to be ready by May 2023. The trial took place at the Alfred Hospital in Melbourne, involving sixteen healthy volunteers. The new safety data will be included in a future IND application to the U.S. FDA.
Arch Biopartners Inc. (ACHFF) announced a significant partnership with the National Research Council of Canada Industrial Research Assistance Program, receiving up to $4,000,000 to enhance the LSALT peptide (Metablok) program aimed at treating acute inflammation in critical organs. The funding will support essential research tasks including dosing studies, Phase III human trials for COVID-19, and Phase II trials for cardiac surgery-related kidney injury. This initiative is expected to propel the drug development process over the next twelve months, with the project term concluding on March 31, 2024.
Arch Biopartners Inc. announced the receipt of a CIHR Project Grant of $1,109,250 for research into dipeptidase-1 (DPEP-1) and its connections to renal inflammation and chronic kidney disease (CKD). The award was given to a team led by Dr. Daniel Muruve at the University of Calgary, who is also Chief Science Officer at Arch. This funding will support efforts to understand how DPEP-1 influences kidney disease, potentially leading to new therapeutic targets. Arch is focused on innovative treatments for organ inflammation, aiming to improve outcomes for conditions like acute kidney injury.
Arch Biopartners Inc. has appointed Mr. Farris Smith from Novo Nordisk Canada Inc. as a Strategic Advisor to enhance corporate activities and business development for their drug candidates. Farris Smith brings extensive experience from various roles within Novo Nordisk, including CFO for Canada. He expressed enthusiasm for collaborating with Arch to advance their innovative treatments targeting organ inflammation. Arch Biopartners is focused on developing therapies for lung, liver, and kidney inflammation through the DPEP-1 pathway. The company currently has 62,330,292 common shares outstanding.
Arch Biopartners has appointed Dr. David Luke as a Strategic Advisor for clinical trial development. Dr. Luke brings over 20 years of experience from Pfizer and other firms, where he oversaw various human trials. His involvement will focus on advancing LSALT peptide, which targets inflammation related to acute kidney injury, following its prior use in COVID-19 trials. Arch Biopartners is dedicated to developing therapies addressing organ inflammation through innovative technologies. The company currently has 62,330,302 shares outstanding.
Arch Biopartners announced Health Canada's approval for the inclusion of its drug candidate LSALT Peptide in the CATCO clinical trial, aimed at treating organ inflammation in COVID-19 patients. The amendment allows LSALT to be used in a new dosing arm, with trials expected to begin after local approvals. The CATCO study involves up to 55 hospitals across Canada and targets approximately 350 patients suffering from complications due to COVID-19. LSALT's focus is on reducing organ inflammation irrespective of COVID-19 variants.
Arch Biopartners announced a publication in Science Advances detailing the mechanism of action of dipeptidase-1 (DPEP-1) in acute kidney injury (AKI). The study, led by Dr. Daniel Muruve, highlights how DPEP-1 regulates inflammation in the kidneys post-injury. It also confirms the protective effects of two DPEP-1 inhibitors, LSALT peptide and cilastatin, during ischemia-reperfusion injury. Arch plans to pursue a phase II trial targeting cardiac surgery-related AKI, providing a significant step forward for developing therapies in this area.
Arch Biopartners Inc. announced that the Research Ethics Board at Sunnybrook Research Institute approved an amendment to the CATCO trial protocol, allowing the inclusion of their lead drug candidate, LSALT Peptide (LSALT), to target acute organ inflammation related to COVID-19. The company will supply LSALT vials for dosing approximately 350 patients. CATCO, a multi-centre study, aims to find new treatments for COVID-19 complications. Arch seeks Health Canada approval before commencing the new dosing arm.